Artemis Medicare Services Records Stellar Growth in Q3 FY23 with 20% Rise in Net Sales
Artemis Medicare Services Limited (AMSL) has delivered impressive financial results for the quarter ending September 2023, showcasing robust growth in key financial metrics. The consolidated net sales for Q3 FY23 stand at Rs 225.01 crore, reflecting a significant year-on-year increase of 20.03% from the corresponding period in 2022 when net sales were reported at Rs 187.46 crore.
The quarterly net profit for September 2023 paints a picture of sustained profitability, reaching Rs 13.59 crore. This represents a remarkable surge of 48.87% compared to the net profit of Rs 9.13 crore in September 2022. The positive momentum extends to EBITDA, which stands at Rs 36.63 crore, marking a robust growth of 47.23% from Rs 24.88 crore in the same quarter last year.
Earnings Per Share (EPS) for AMSL witnessed a notable uptick, reaching Rs 1.00 in September 2023, compared to Rs 0.68 in September 2022. This rise in EPS underscores the company's ability to generate higher earnings for its shareholders.
has been equally impressive, with AMSL shares closing at Rs 153.55 on November 8, 2023, on the National Stock Exchange (NSE)
. Over the past six months, the stock has yielded substantial returns of 84.78%, and over the last 12 months, an impressive 100.46%.
This financial success underscores Artemis Medicare Services' resilience and strategic acumen in navigating the business landscape. The positive trajectory in net sales, net profit, and market performance attests to the company's commitment to sustainable growth and value creation for its stakeholders.
As AMSL continues to scale new heights, these financial indicators position the company as a formidable player in the healthcare industry, showcasing its ability to thrive in dynamic market conditions. Investors and stakeholders can look forward to sustained growth and value appreciation as Artemis Medicare Services
continues its trajectory of financial excellence.